Tscan therapeutics announces fda clearance of investigational new drug application for tsc-200-a0201 targeting hpv16 to treat solid tumors

Tsc-200-a0201 is tscan's third cleared ind for the t-plex solid tumor program supporting the use of multiple tcrs in combination to deliver customized, multiplexed tcr-t cell therapies based on target and hla expression tsc-200-a0201 is tscan's third cleared ind for the t-plex solid tumor program supporting the use of multiple tcrs in combination to deliver customized, multiplexed tcr-t cell therapies based on target and hla expression
TCRX Ratings Summary
TCRX Quant Ranking